Compare AstraZeneca plc (AZN) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Hormel Foods Corp — how do they compare? AstraZeneca plc trades at $158.25 (market cap $248.14B), while Hormel Foods Corp trades at $24.28 (market cap $13.37B). The key difference: AstraZeneca plc is far larger — about 18.6× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| AZN | HRL | |
|---|---|---|
Market Cap | $248.14B | $13.37B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $29.25 |
52-Week Low | $147.06 | $19.74 |
Enterprise Value | $275.41B | $15.37B |
Dividend Yield | 2.01% | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Hormel Foods (HRL) trades at $24.23, down 1.92% over 24 hours, amid a bearish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $0.40 surpassing the $0.3544 estimate. Revenue for 2025 was $12.11B, though net income margin compressed to 3.82%. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its CERATTI business in Brazil.
HRL presents a mixed outlook with a defensive profile as a consumer staple, supported by a 4.6% dividend yield. However, margin pressures and a bearish technical trend pose near-term risks. The consensus price target of $26.33 implies modest upside, but investor sentiment remains cautious given high hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
